Trial Profile
Treatment and outcomes in patients with chronic myeloid leukemia treated first line therapy with Imatinib and with second generation tyrosine kinase inhibitors:EUTOS population-based registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2019
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary) ; Protein tyrosine kinase inhibitors
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms EUTOS